Who Owns Motrin?

• Parent Company: Kenvue
• Ownership Type: Wholly owned
• Company Type: Publicly Traded
• Stock Ticker: NYSE: KVUE

• Founded: 1974
• Founders: Upjohn Company (original developer)

• Founded: 2023
• Headquarters: Jersey City, New Jersey, USA
• Company Type: Publicly Traded
• Stock: NYSE: KVUE
• Revenue: approximately $14.9 billion (FY2024)
• Employees: Approximately 22,000

Visit Kenvue website

• Headquarters: Summit, New Jersey, USA
• Manufacturing / Operations: United States, Puerto Rico, Europe, Asia

Motrin has established sustainability initiatives as part of Kenvue's comprehensive Healthy Lives Mission strategy, focusing on renewable energy adoption, recyclable packaging, and carbon reduction across manufacturing operations. The brand benefits from Kenvue's commitment to environmental responsibility while maintaining its position as a trusted ibuprofen pain relief medication for millions of consumers worldwide.

The company's sustainability approach is demonstrated through Kenvue's achievement of reducing Scope 1 and 2 emissions by 37% from a 2020 base year, working toward a 42% reduction goal by 2030. Kenvue has expanded the use of renewable electricity to 72% across global operations, with Latin America maintaining 100% renewable electricity since 2023. These environmental achievements directly benefit Motrin's manufacturing processes and distribution networks.

Motrin's packaging sustainability has improved significantly through Kenvue's transition of 69% of packaging across portfolios to be recyclable or refillable, with a goal of 100% by 2025. The company has reduced the use of virgin plastic in packaging by more than 21.4% from a 2020 base year, with goals of 25% by 2025 and 50% by 2030. These initiatives address growing consumer concerns about plastic waste in the pharmaceutical and consumer healthcare sectors.

Kenvue's Sustainable Innovation Profiler, a patent-pending tool designed to measure a product's environmental performance, has been integrated into research and development processes across all brands including Motrin. This tool enables developers to make real-time choices to design solutions that benefit both people and the planet, ensuring that new Motrin formulations and packaging innovations meet environmental performance standards.

The company's sustainability strategy extends beyond environmental initiatives to include social responsibility through Kenvue's Healthy People pillar. This includes healthcare professional training programs, community health initiatives, and support for various health causes. In 2024, Kenvue donated more than $56 million to support communities in need, demonstrating the company's commitment to social responsibility across its brand portfolio.

However, Motrin faces significant ethical challenges related to medication safety and FDA regulatory requirements. The FDA has strengthened warnings that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, can cause heart attacks or strokes. These strengthened warnings have increased scrutiny of Motrin's safety labeling and marketing practices, requiring enhanced consumer education about proper usage and potential risks.

The brand must balance its role in providing effective pain relief with the responsibility to ensure consumer safety through clear labeling, appropriate dosage recommendations, and comprehensive risk communication. This balance creates ongoing ethical challenges in marketing pain relief medications while maintaining consumer trust and regulatory compliance.

Motrin has received recognition for pain relief effectiveness and consumer trust, though recent FDA safety warnings have impacted some safety considerations. The brand's long-standing presence in the consumer healthcare market has been acknowledged by healthcare professionals and consumer organizations for providing reliable ibuprofen-based pain relief for various conditions.

The brand's effectiveness in treating pain and inflammation has been recognized by medical professionals and healthcare organizations, with Motrin being recommended as a trusted over-the-counter pain relief option. The brand's consistent quality and effectiveness have earned it a position as one of the leading ibuprofen pain relief brands globally, competing directly with Advil and generic ibuprofen products.

Motrin's parent company, Kenvue, has received recognition for sustainability initiatives and environmental leadership in the consumer healthcare sector. Kenvue's Healthy Lives Mission Report and sustainability achievements have been acknowledged by environmental organizations and industry analysts for demonstrating corporate responsibility in addressing climate change and plastic waste challenges.

The company's workplace culture and employee development programs have received recognition for diversity and inclusion initiatives, with Kenvue being acknowledged as a leading employer in the consumer healthcare sector. The company's training programs and career advancement opportunities have been recognized for developing talent in pharmaceutical research, development, and marketing.

However, the FDA's strengthened warnings on NSAIDs and related safety concerns have led to increased scrutiny from regulatory bodies and consumer safety organizations, potentially impacting future consideration for safety awards. While Motrin continues to receive recognition for pain relief effectiveness, the safety warnings have created challenges in maintaining consumer trust and regulatory compliance.

FDA Strengthened NSAID Warnings: The FDA has strengthened warnings that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen found in Motrin, can cause heart attacks or strokes. These strengthened warnings have increased regulatory scrutiny of Motrin's safety labeling and marketing practices, requiring enhanced consumer education about proper usage and potential cardiovascular risks.

Generic Medication Quality Issues (2025): In April 2025, dozens of generic medications were recalled due to quality concerns, creating increased scrutiny of the entire over-the-counter medication market. While Motrin was not directly affected by these recalls, the incident led to heightened consumer awareness about medication quality and safety standards across the pain relief category.

Ibuprofen Allergy and Side Effect Concerns: Motrin faces ongoing challenges related to ibuprofen allergies and potential side effects. The FDA requires ibuprofen products to include allergy alerts warning that the medication may cause severe allergic reactions, especially in people allergic to aspirin. These concerns require comprehensive labeling and consumer education about potential adverse reactions.

Regulatory Scrutiny Over Dosage Limits: Motrin has faced regulatory scrutiny regarding dosage limits and safety warnings, particularly around long-term use of ibuprofen products. The FDA requires specific labeling about maximum daily doses and potential risks associated with exceeding recommended amounts, creating compliance challenges for the brand's marketing and educational materials.

Price Pressure from Generic Alternatives: Motrin faces significant competitive pressure from generic ibuprofen alternatives that offer similar pain relief at lower prices. This price pressure creates challenges in maintaining market share while justifying the brand premium through quality assurances and consumer trust.

Cardiovascular Risk Communication: The FDA's requirement for boxed warnings regarding potential cardiovascular dangers of NSAIDs creates ongoing communication challenges for Motrin. The brand must balance providing effective pain relief with comprehensive risk communication while maintaining consumer confidence in product safety.

Product Safety and Liability Concerns: Motrin faces potential liability issues related to adverse reactions and improper use of ibuprofen products. The brand must maintain comprehensive safety monitoring and rapid response protocols for any safety concerns that emerge from consumer use or regulatory findings.

Competition from Prescription Alternatives: Motrin faces competition from prescription-strength pain relievers and alternative pain management solutions, creating challenges in maintaining its position as a preferred over-the-counter option for various pain conditions.

Supply Chain and Manufacturing Quality: The brand must maintain rigorous quality control standards across its manufacturing processes to ensure product consistency and safety, particularly given the heightened scrutiny of medication quality following various generic drug recalls in 2025.

Consumer Education and Proper Use: Motrin faces ongoing challenges in educating consumers about proper ibuprofen usage, including dosage guidelines, timing of doses, and potential interactions with other medications. This educational responsibility creates both ethical obligations and operational challenges for the brand's marketing and customer service efforts.